Oxalee Drug Interactions

Fluorouracil: Pharmacokinetic interaction with 5-FU is unlikely when recommended dosages and administration schedule are used. Potential pharmacokinetic interaction (20% increase in plasma 5-FU concentrations) during concomitant use of 5-FU and 130 mg/m² of oxaliplatin every 3 weeks.
Anticoagulants: Prolonged time and INR occasionally associated with hemorrhage in patients who received oxaliplatin plus 5-fluorouracil/leucovorin while on anticoagulants. Patients receiving oxaliplatin plus 5-FU/leucovorin and requiring oral anticoagulants may require close monitoring.
Nephrotoxic drugs: Nephrotoxic drugs may decrease the clearance of platinum-containing compounds; however, this interaction has not been specifically studied.
Protein-bound drugs: In vitro, no significant displacement of oxaliplatin binding to plasma proteins has been observed with the following agents: erythromycin, salicylates, granisetron, paclitaxel, and sodium valproate.
Drugs that may cause QT prolongation and rhabdomyolysis: Caution is advised when oxaliplatin is co-administered with other drugs known to cause QT prolongation and rhabdomyolysis (see Precautions).